Dr. Maureen Dower Joins PetVivo Holdings, Inc. as a Senior Technical Services Veterinarian
June 01 2023 - 8:00AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company")
an emerging biomedical device company focused on the
commercialization of innovative medical devices and therapeutics
for companion animals and animal athletes is pleased to announce
that Dr. Maureen Dower has accepted a position with the Company as
its new Senior Technical Services Veterinarian.
"We are thrilled to have Maureen join the
PetVivo team.” said John Lai, Chief Executive Officer of PetVivo
Holdings, Inc. “Dr. Dower brings a wealth of experience to our team
as an expert in biovigilance systems, veterinary products customer
service, as well as the therapeutic treatment of animals."
Dr. Dower has more than 20 years of veterinary
experience in the Animal Health Industry holding various roles as a
practicing veterinarian, as well as a key contributor in customer
service of therapeutic veterinary products and the implementation
and customization of pharmacovigilance systems in companies
developing and commercializing veterinary products. Dr. Dower has
served in various capacities, contributing to product development,
regulatory guidance, technical sales training and customer service
with companies such as Pfizer Animal Health and Zoetis Animal
Health. Dr. Dower’s involvement with some of the leading brands for
veterinary products brings a wealth of experience to PetVivo. Dr.
Dower has a degree in animal sciences from Penn State University
and a Doctorate of Veterinary Medicine from Purdue University
School of Veterinary Medicine.
“I am incredibly excited and honored to join the
PetVivo team to assist in demonstrating to veterinarians and the
world the therapeutic benefits of SPRYNG™. My goal is to be a
resource for veterinarians, to provide information and support
their use of Spryng, improving the quality of life and restoring
athletic ability to horses, dogs and other animals living with
osteoarthritis and other lameness issues,” said Dr. Dower. “I am
confident that SPRYNG will enhance the lives of animals, as well as
their owners.”
For more information about PetVivo Holdings,
Inc. and its innovative product, Spryng, please contact
info1@petvivo.com or visit https://petvivo.com/ and
https://sprynghealth.com/.
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG, a
veterinarian-administered, intraarticular injection for the
treatment of lameness and other joint related afflictions,
including osteoarthritis, in dogs and horses, is currently
available for commercial sale to veterinarians.
CONTACT:John Lai, CEOPetVivo Holdings,
Inc.Email: info1@petvivo.com(952) 405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements,
including the potential listing of the Company’s common stock on
Nasdaq, are based on information currently available the Company
and its current plans or expectations and are subject to a number
of uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2022 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jun 2024 to Jul 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2023 to Jul 2024